NASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free SRPT Stock Alerts $133.66 +3.03 (+2.32%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$131.16▼$134.4750-Day Range$115.62▼$141.5352-Week Range$55.25▼$159.89Volume1.20 million shsAverage Volume1.02 million shsMarket Capitalization$12.63 billionP/E Ratio1,215.09Dividend YieldN/APrice Target$156.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Sarepta Therapeutics alerts: Email Address Sarepta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.79 Rating ScoreUpside/Downside20.2% Upside$160.60 Price TargetShort InterestBearish5.15% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment0.38Based on 41 Articles This WeekInsider TradingSelling Shares$2.74 M Sold Last QuarterProj. Earnings Growth224.41%From $2.13 to $6.91 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.23 out of 5 starsMedical Sector817th out of 5,430 stocksPharmaceutical Preparations Industry277th out of 2,526 stocks 3.4 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.15% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Sarepta Therapeutics has recently increased by 5.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 1.9 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 41 news articles for Sarepta Therapeutics this week, compared to 10 articles on an average week.Search InterestOnly 16 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,739,419.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 224.41% in the coming year, from $2.13 to $6.91 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is 1,215.09, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 146.34.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is 1,215.09, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 263.69.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 14.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsFW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. About Sarepta Therapeutics Stock (NASDAQ:SRPT)Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More SRPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRPT Stock News HeadlinesMay 4, 2024 | americanbankingnews.comQ3 2024 Earnings Estimate for Sarepta Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:SRPT)May 3, 2024 | bizjournals.comDrug watchdog criticizes Sarepta gene therapy approval, costMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...May 3, 2024 | finance.yahoo.comGene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global HealthMay 3, 2024 | businesswire.comGene Therapy Pioneer Jerry R. Mendell, M.D.May 3, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up Following Earnings BeatMay 2, 2024 | msn.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comBuy Rating on Sarepta Therapeutics Affirmed Amid Elevidys Regulatory Progress and Portfolio StrengthMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...May 2, 2024 | benzinga.comWhat Analysts Are Saying About Sarepta Therapeutics StockMay 2, 2024 | msn.comSarepta Elevidys accelerated approval criticized by ICER execMay 2, 2024 | finance.yahoo.comSarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley SaysMay 2, 2024 | markets.businessinsider.comBuy Rating on Sarepta Therapeutics Amid Anticipated Label Expansion for ElevidysMay 2, 2024 | finance.yahoo.comQ1 2024 Sarepta Therapeutics Inc Earnings CallMay 2, 2024 | finance.yahoo.comSarepta Therapeutics Inc (SRPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...May 2, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Sarepta Therapeutics, Inc. Decreased by Analyst (NASDAQ:SRPT)May 2, 2024 | gurufocus.comQ1 2024 Sarepta Therapeutics Inc Earnings Call TranscriptMay 1, 2024 | msn.comSarepta Therapeutics (SRPT) Q1 2024 Earnings Call TranscriptMay 1, 2024 | investorplace.comSRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | markets.businessinsider.comSarepta Therapeutics Q1 Earnings SummaryMay 1, 2024 | finance.yahoo.comSarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate DevelopmentsMay 1, 2024 | americanbankingnews.comZacks Research Research Analysts Raise Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)April 30, 2024 | businesswire.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 30, 2024 | markets.businessinsider.comHere's what to expect from Sarepta Therapeutics's earnings reportApril 26, 2024 | bizjournals.comState’s highest paid CEO reports major drop in compensationApril 26, 2024 | americanbankingnews.comEquities Analysts Set Expectations for Sarepta Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:SRPT)April 26, 2024 | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Moderate Buy" by BrokeragesSee More Headlines Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/03/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,314Year Founded1980Price Target and Rating Average Stock Price Target$160.60 High Stock Price Target$224.00 Low Stock Price Target$109.00 Potential Upside/Downside+17.2%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($6.12) Trailing P/E Ratio1,215.09 Forward P/E Ratio62.75 P/E GrowthN/ANet Income$-535,980,000.00 Net Margins1.20% Pretax Margin-41.83% Return on Equity2.32% Return on Assets0.58% Debt Debt-to-Equity Ratio1.32 Current Ratio3.95 Quick Ratio3.45 Sales & Book Value Annual Sales$1.40 billion Price / Sales9.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.19 per share Price / Book14.54Miscellaneous Outstanding Shares94,506,000Free Float87,513,000Market Cap$12.63 billion OptionableOptionable Beta0.95 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Douglas S. Ingram Esq. (Age 61)President, CEO & Director Comp: $1.62MMr. Ian Michael Estepan (Age 48)Executive VP & CFO Comp: $917.53kDr. Louise R. Rodino-Klapac Ph.D. (Age 46)Executive VP, Chief Scientific Officer and Head of Research & Development Comp: $1.04MMr. Ryan E. Brown J.D. (Age 46)Executive VP, General Counsel & Corporate Secretary Comp: $823.36kMr. Bilal Arif (Age 52)Executive VP & Chief Technical Operations Officer Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsMs. Alison NasisiExecutive VP & Chief People OfficerDr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExecutive VP & Chief Customer OfficerMr. Will TiltonSenior VP, Head of Strategy & Chief of StaffMore ExecutivesKey CompetitorsDr. Reddy's LaboratoriesNYSE:RDYKaruna TherapeuticsNASDAQ:KRTXUnited TherapeuticsNASDAQ:UTHRCatalentNYSE:CTLTViatrisNASDAQ:VTRSView All CompetitorsInsiders & InstitutionsGSA Capital Partners LLPSold 1,589 shares on 5/3/2024Ownership: 0.005%Central Pacific Bank Trust DivisionBought 3,228 shares on 5/3/2024Ownership: 0.003%TobamSold 36,138 shares on 5/2/2024Ownership: 0.127%Nordea Investment Management ABBought 33,711 shares on 5/2/2024Ownership: 0.065%Connecticut Wealth Management LLCBought 2,013 shares on 5/1/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions SRPT Stock Analysis - Frequently Asked Questions Should I buy or sell Sarepta Therapeutics stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SRPT shares. View SRPT analyst ratings or view top-rated stocks. What is Sarepta Therapeutics' stock price target for 2024? 14 brokers have issued 1 year price targets for Sarepta Therapeutics' stock. Their SRPT share price targets range from $109.00 to $224.00. On average, they expect the company's share price to reach $160.60 in the next year. This suggests a possible upside of 20.2% from the stock's current price. View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts. How have SRPT shares performed in 2024? Sarepta Therapeutics' stock was trading at $96.43 on January 1st, 2024. Since then, SRPT stock has increased by 38.6% and is now trading at $133.66. View the best growth stocks for 2024 here. When is Sarepta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our SRPT earnings forecast. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday, May, 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.84. The biotechnology company earned $413.50 million during the quarter, compared to analysts' expectations of $375.52 million. Sarepta Therapeutics had a trailing twelve-month return on equity of 2.32% and a net margin of 1.20%. The business's revenue for the quarter was up 63.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.44) earnings per share. What ETFs hold Sarepta Therapeutics' stock? ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Simplify Health Care ETF (PINK), Morningstar US Small Growth (MSGR), iShares Genomics Immunology and Healthcare ETF (IDNA), iShares Neuroscience and Healthcare ETF (IBRN), Global X Genomics & Biotechnology ETF (GNOM), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH). What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS). Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.47%), Allspring Global Investments Holdings LLC (0.28%), Allspring Global Investments Holdings LLC (0.28%), Tobam (0.13%), Simplex Trading LLC (0.00%) and Mirae Asset Global Investments Co. Ltd. (0.10%). Insiders that own company stock include Bilal Arif, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Ian Michael Estepan, Kathryn Jean Boor, Louise Rodino-Klapac, Michael Andrew Chambers, Richard Barry and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.Read More This page (NASDAQ:SRPT) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGold ManiaStansberry ResearchThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.